Current pharmacotherapy of depression - focused on multimodal/multifunctional antidepressants

Warning

This publication doesn't include Institute of Computer Science. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors	ČEŠKOVÁ Eva
Year of publication	2016
Type	Article in Periodical
Magazine / Source	EXPERT OPINION ON PHARMACOTHERAPY
MU Faculty or unit	Central European Institute of Technology
Citation
web	http://www.tandfonline.com/doi/full/10.1080/14656566.2016.1219340?scroll=top&needAccess=true
Doi	https://doi.org/10.1080/14656566.2016.1219340
Field	Pharmacology and pharmaceutical chemistry
Keywords	Depressive disorder; pharmacoresistance; multimodal; multifunctional antidepressants; pharmacogenomic tests
Description	Major depressive disorder (MDD) is a widespread disease, with a lifetime prevalence of 15% and an annual incidence of approximately 7%. It is associated with significant costs in quality of life, loss of work productivity, and a high risk of mortality. It is predicted to become the leading cause of disability in Western countries by 2030.
Related projects:	CEITEC 2020